HCPCS Level II code Q5114 identifies the biosimilar trastuzumab-dkst (Ogivri) in a 10 mg unit for injectable administration. This code is used when billing for the specific trastuzumab biosimilar product rather than the reference biologic, and it matters nationally because trastuzumab biosimilars are integral to breast and gastric cancer therapy regimens and to payer efforts to manage biologic drug costs. The code facilitates tracking of biosimilar utilization and supports reimbursement for outpatient infusion services.

Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for payer coverage and common billing practices, a concise clinical context describing the therapeutic role of trastuzumab biosimilars, and relevant coding considerations such as appropriate unit reporting for drug billing. The summary also highlights where input is limited: specific payer policies, utilization data, and associated ICD-10 diagnoses are not available in the input.

This publication is intended for a national audience of billing managers, oncology clinic administrators, and policy analysts seeking a clear description of HCPCS Level II code Q5114, its clinical use, and the payer landscape relevant to biosimilar trastuzumab in outpatient infusion settings.